cediranib maleate + temozolomide

Cediranib maleate + temozolomide is a combination therapy under investigation primarily for the treatment of glioblastoma and other advanced solid tumors. Cediranib maleate is an oral small molecule inhibitor that targets all three vascular endothelial growth factor (VEGF) receptors, thereby inhibiting angiogenesis and reducing blood supply to tumors. Temozolomide is an oral alkylating agent of the imidazotetrazine class that acts as a prodrug; it methylates DNA at guanine residues, leading to tumor cell death through DNA damage. The combination aims to enhance antitumor efficacy by simultaneously disrupting tumor vasculature (cediranib) and directly damaging tumor DNA (temozolomide). This regimen has been studied in conjunction with radiation therapy for newly diagnosed glioblastoma[2][3]. Cediranib was developed by AstraZeneca.

Brand names

RecentinTemodar

Other names

cediranib + temozolomideAZD2171 + TMZ